Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Wuhan Hiteck Biological Pharma Co., Ltd specializes in the development and manufacturing of biological pharmaceuticals, particularly in the fields of vaccines and monoclonal antibodies. The company operates primarily in China, leveraging its R&D capabilities to address local healthcare needs, but has faced significant revenue declines recently due to increased competition and regulatory challenges.
Wuhan Hiteck generates revenue through the sale of its proprietary biological drugs and vaccines, alongside contract manufacturing services for other pharmaceutical companies. Its competitive advantages include a strong R&D pipeline and established relationships with local healthcare providers, although it faces pricing pressures from generic competitors.
Regulatory approvals for new drugs and vaccines
Changes in healthcare policy affecting drug pricing
Competitive landscape shifts, particularly from generic entrants
Partnerships or collaborations with larger pharmaceutical firms
Regulatory changes that could impact drug approval processes
Technological disruption in drug development methodologies
Increased competition from generic drug manufacturers
Potential market entry of larger multinational pharmaceutical companies
Negative operating cash flow impacting liquidity
High reliance on R&D spending without immediate revenue return
moderate - The demand for pharmaceuticals is somewhat insulated from economic cycles, but significant downturns can impact healthcare budgets.
The company's low debt levels (Debt/Equity of 0.01) mean that rising interest rates have minimal direct impact on financing costs, but they could affect overall market valuations.
minimal - The company does not rely heavily on credit for operations, given its low debt levels.
value - Investors may be attracted to the low valuation metrics despite current operational challenges.
high - The stock has shown significant volatility with a 3-month return of -28.8%.
